

---

**Osteoporosis in Men and Women: An Update on Diagnosis and Management for Fracture Prevention: Part 2**

**Nancy R. Berman MSN, ANP-BC, MSCP, FAANP**  
 Adult Nurse Practitioner/Colposcopist  
 Certified Menopause Practitioner (NAMS)  
 Millennium Affiliated Physicians  
 Division of Michigan Healthcare Professionals  
 Farmington Hills, Michigan  
 Clinical Instructor  
 Department of Obstetrics and Gynecology  
 Wayne State University School of Medicine  
 Detroit, Michigan

---

1

---

**Disclosures**

Advisory Board:  
 Astellas

Speakers Bureau:  
 Astellas

---

2

---

**Pharmacologic Therapy**

Level of risk and the choice of agents

---

3

---

**Risk Stratification and Treatment Decisions**

> **Low risk**

- No prior fracture, and T-score  $\geq -1$  and FRAX < 20% MOF, <3% Hip
- Non-pharmacologic treatment. No pharmacologic treatment needed

> **Moderate risk**

- No prior fracture and T-score between -1 and -2.5 and FRAX probabilities <20%MOF, <3% Hip
- Some may benefit from sequential antiresorptive monotherapy especially those with BMD close to -2.5
  - Estrogen in early menopause
  - Raloxifene in 50's to 60's
  - Bisphosphonates mid/late 60's

---

Canacho PM, Finkel SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

4

---

**Osteoporotic Patients: Level of Risk and Choice of Pharmacologic Agent**

**High Risk** (not meeting previous criteria but diagnosed with osteoporosis):

- >Postmenopausal women or men over age 50 with a prior hip or spine fracture
- >Postmenopausal women or men over 50 with a BMD T-score of -2.5 or lower at the hip or spine
- >Postmenopausal women or men over 50 with T-score between -1 and -2.5 at the femoral neck, total hip, or spine if:
  - 10 year probability (from FRAX) of hip fracture is  $\geq 3\%$
  - 10 year probability of a major osteoporosis-related fracture is  $\geq 20\%$

---

Canacho PM, Finkel SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

5

---

**Risk Stratification and Treatment Decisions**

**High risk**

- > Older single prior fracture (> 2 years earlier) or T-score -2.5 or T-score -1 to -2.5 with FRAX  $\geq 20\%$  MOF or  $\geq 3\%$  Hip

Goal: Improve BMD to T-score > -2.5 and reduce fracture risk

- Younger women may benefit from estrogen/raloxifene especially if spine T-score is low and hip is > -2.5
- Usually bisphosphonates or denosumab
- Anabolic agents are appropriate for some

---

Canacho PM, Finkel SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

6

## Osteoporotic Patients: Level of Risk and Choice of Pharmacologic Agent

### Very High Risk:

- > Recent fracture (within the last 12 months)
- > Fractures while on approved drug therapy, multiple fractures, fractures while on drugs causing skeletal harm (i.e. glucocorticoids)
- > Very low T-score (e.g. less than -3.0)
- > High risk for falls or history of injurious falls
- > Very high fracture probability by FRAX
  - Major osteoporotic fracture >30%
  - Hip fracture >4.5%

Canacho PM, Patel SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update. *Endocrine Practice*, 2020;26:5-6.

7

## Choosing a Pharmacologic Agent

Approved agents with efficacy to reduce hip, nonvertebral and spine fractures as initial therapy:

- > High fracture risk:
  - Alendronate, risedronate, zoledronate, denosumab appropriate
- > Very high fracture risk:
  - Abaloparatide, denosumab, romosozumab, teriparatide, and zoledronic acid
    - And consider for patients who are unable to tolerate oral therapy

Canacho PM, Patel SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update. *Endocrine Practice*, 2020;26:5-6.

8

## Anabolic Agents and Treatment Sequence in Appropriate Patients

- > Recent trials have changed the thinking on when to use anabolic agents:
  - Not a drug of "last resort"
  - After multiple fractures
  - Failure of other medications
- > The three anabolic agents (teriparatide, abaloparatide and romosozumab) reduce non-vertebral and vertebral fractures faster and to a greater extent than potent antiresorptive agents

Cosman F. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. *Endocrine Practice*, Accepted for Publication, 2020.

9

## Anabolic Agents and Treatment Sequence in Appropriate Patients

- > Sequence of drug therapy matters
  - Bone density accrual is maximized when the anabolic agent is given first and followed with antiresorptive therapy
  - Total hip score is considered the best measurement for future fracture risk
  - Obtaining a greater hip BMD is a treatment goal for high risk osteoporosis patients

Cosman F. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. *Endocrine Practice*, Accepted for Publication, 2020.

10

## Anabolic Agents and Treatment Sequence in Appropriate Patients

Identifying appropriate patients for anabolic therapy:

- > Patients with prior fractures
- > Patients who present with very low BMD (T-score below -3.0) even in the absence of prior fracture
  - Especially with other risk factors such as advanced age, high fall risk, physical or cognitive disability

Cosman F. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. *Endocrine Practice*, Accepted for Publication, 2020.

11

## Initiating Pharmacologic Therapy: Case Examples

Fracture risk	Case example	Initial treatment consideration
Moderate	80-year-old female; lumbar spine T score -2.2; femoral neck T score -1.2	Raloxifene (especially if patient is interested in breast cancer prevention) or a bisphosphonate
High	70-year-old female; femoral neck T score -2.7; history of hip fracture in parent	Bisphosphonate if no significant renal dysfunction (oral if tolerated or IV infusion) or denosumab
High	80-year-old female; lumbar spine T score -0.9; femoral neck T score -1.7; FRAX score: major osteoporotic fracture 10-year risk: 15%; hip fracture 10-year risk: 3.9%	Bisphosphonate if no significant renal dysfunction (oral if tolerated or IV infusion) or denosumab
Very high	78-year-old female; femoral neck T score -3.1; vertebral compression fracture diagnosed on x-ray	Consider sequencing with teriparatide, abaloparatide, or romosozumab initially and follow with a maintenance antiresorptive drug

12

### Monitoring Pharmacologic Treatment

- > Repeat DXA every 1 to 2 years until findings are stable
- > The 1/3 radius may be considered as an alternate site when the lumbar spine/hip are not evaluable
- > Continue to follow every 1 to 2 years depending on the clinical circumstances
- > Bone turnover markers may be used to assess patient compliance and efficacy of therapy.

Canacho PM, Pask SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

13

### How to Determine if Treatment is Successful

- > Stable or increasing bone mineral density
- > No evidence of new fractures or vertebral fracture progression
- > One new fracture may not necessarily be evidence of treatment failure
- > Consider two or more fragility fractures as evidence of treatment failure

Canacho PM, Pask SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

14

### Length of Treatment

- > Abaloparatide and teriparatide treatment is 2 years
  - Follow with a bisphosphonate or denosumab
- > Romosozumab is 1 year and follow with a drug intended for long term use
- > Oral bisphosphonate
  - Consider drug holiday after 5 years if fracture risk is no longer high
    - Such as T- score is greater than -2.5
    - No fractures
  - Continue up to 10 years if fracture risk remains high

Canacho PM, Pask SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

15

### Length of Treatment

- > Oral therapy
  - Consider a drug holiday after 6 to 10 years of stability in patients with very high fracture risk
- > IV infusion with zoledronic acid
  - Consider a drug holiday after 3 years in high-risk patients or until fracture risk is no longer high
  - Continue up to 6 years in very-high risk patients

Canacho PM, Pask SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

16

### Drug Holiday

- > End is based on individual patient circumstances such:
  - An increase in fracture risk
  - Decrease in bone mineral density
  - Increase in bone turnover markers
- > **NEVER START A DRUG HOLIDAY WITH NON-BISPHOSPHONATE ANTIRESORPTIVE DRUGS**
- > If denosumab is discontinued, patient should be transitioned to another antiresorptive

Canacho PM, Pask SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update, endocrine Practice, 2020;26:5-6.

17

### Addressing Recent Controversies in the Treatment of Osteoporosis

18

## Addressing Recent Controversies

- > Long term use of bisphosphonate therapy
- > Bisphosphonate therapy and the occurrence of fractures of the subtrochanteric or diaphyseal femur
- > Osteonecrosis of the jaw (ONJ)

19

## Bisphosphonates

- > Concerning adverse effects:
  - Osteonecrosis of the jaw
    - Risk 1:1,000 to 1:263,000
    - Not associated with treatment duration
    - Potential risk factors include poor oral hygiene, glucocorticoid therapy, and chemotherapy
  - Atypical femur fractures
    - Risk increases with longer therapy duration
    - Subtrochanteric and diaphyseal femoral fractures
- > Bisphosphonates accumulate in the bone, so drug holidays are recommended to reduce long-term risk

Nichols M, et al. Am J Med. 2013;126(1):13-20.

20

## Addressing Recent Controversies

- > Treatment decisions require risk and benefit discussions
- > What was acceptable risk previously, may no longer be acceptable
- > If disease state risk is high: *fracture*
  - Risk of rare complications may be outweighed

21

## Drug Holiday Recommendations

Risk level for fracture	Initiate drug holiday	Therapy during holiday	Length of holiday
High risk	After 5 y of stability on oral treatment or after 3 y with intravenous zoledronic acid	None	Individualize to patient risk
Very high risk and remains at high risk	After 10 y of oral therapy or after 6 y for intravenous zoledronic acid	Consider teriparatide	Individualize to patient risk

Chesnut CH, Perin SL, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Postmenopausal Osteoporosis: 2002 Update. *Endocrine Practice*. 2002;8:26-54.

22

## Effective Patient Management in the Primary Care Setting

23

## Effective Patient Management in the Primary Care Setting

Patients may need in depth counseling on why treatment is recommended:

- > Patients may not be compliant to treatment regimens if they do not understand the risk of something (low bone mass) and increased fracture risk, when they don't feel symptoms
- > Based on a patient's level of education, they may require more detail on their BMD, FRAX or treatment recommendations

THIS REQUIRES TIME!

24

### Osteoporosis and Fracture Prevention in the Primary Care Setting

---

- Patients need to participate in shared decision making regarding starting pharmacologic therapy as treatment or for preventative care for significant 10 year fracture risk
  - **Patients need to understand the idea of risk and benefit when they decide whether they will take medication**
- 

25

### Educational Gaps and Opportunities

---

- > Current guidelines for who to screen
    - Decreased reimbursement by Medicare for bone densitometry
    - Underscreening of women and men and low rate of Medicare coverage
  - > Current guidelines for who to treat:
    - Identification of patients who are untreated after a hip or spine fracture
    - Identification of patients who have not had appropriate BMD testing
    - Utilization of FRAX to identify osteoporotic patients who are not yet osteoporotic by T- score
- 

26

### Educational Gaps and Opportunities

---

- > Keeping up with controversies and options for changing medication, drug holiday and continuation of rank ligand inhibitor
  - > Consideration of anabolic agents in appropriate patients and setting up a referral source if the clinician is not comfortable initiating the treatment
  - > Having dialogue with specialists when indicated for consultation on appropriate therapy with chronic kidney disease and other conditions
  - > The need for individualization of treatment plan includes the need to avoid overtreatment
- 

27

### Potential Missed Opportunities!

---

- > BMD testing in women 65 and older
  - > BMD testing in men 70 and older
  - > Treatment of men and women at high 10 year fracture risk by FRAX who are not yet osteoporotic
  - > Vertebral or hip fracture history
  - > Women on aromatase inhibitor therapy
  - > Men on androgen-deprivation therapy for prostate cancer
  - > Men and women on glucocorticoid therapy
- 

28

### Summary

---

- > Osteoporosis is under diagnosed and preventative care is under utilized
  - > Current practice requires dialogue between patient and practitioner in regards to individual risk and benefits of therapeutic options
  - > Treatment strategies must be individualized to obtain greater compliance to therapy
  - > Practitioners will need to stay current while treatment recommendations continue to be reviewed and possibly changed
- 

29

### Cases: **Very high risk for fracture**

---

BMD  
FRAX  
The Art of Managing Osteoporosis and Fracture Prevention!

---

30

### Case #1

76 yo Caucasian female: menopause at age 55. 64 inches tall, 170 lbs. hypertensive, hyperlipidemia, type 2 DM.

10/7/21 BMD: right and left hip: -2.0 and -3.2  
right and left femoral neck: -3.0 and -4.0

Change from BMD: 10/14/15  
LS 2.9%, left femoral neck -20.3%, right femoral neck -10.4%

FRAX: Major osteoporotic fracture: 35.8%

Hip: 19.9%

31

### Case #1

- > What is her fracture risk?
- > What is the patient's desire for treatment
- > What is the patient's insurance coverage?
- > What are the important medical history questions?
- > What labs would you draw?
- > How would you treat this patient?
- > Would you refer this patient?

32

### Case #1

Country: US (Caucasian) Name/ID: About the risk factors

Questionnaire:

1. Age (between 40 and 90 years) or Date of Birth: 76 y, 11 m, 11 d  
2. Sex:  Male  Female  
3. Weight (kg): 77.1  
4. Height (cm): 162.6  
5. Previous Fracture:  No  Yes  
6. Parent Fractured Hip:  No  Yes  
7. Current Smoking:  No  Yes  
8. Glucocorticoids:  No  Yes  
9. Rheumatoid arthritis:  No  Yes  
10. Secondary osteoporosis:  No  Yes  
11. Alcohol 3 or more units/day:  No  Yes  
12. Femoral neck BMD (g/cm<sup>2</sup>): 0.677 T-score: -1.0  
13. Calcitonin:  No  Yes  
14. Calcitriol:  No  Yes  
15. Calcitonin Receptor Modulator:  No  Yes  
16. Vitamin D:  No  Yes  
17. Vitamin K:  No  Yes  
18. Vitamin E:  No  Yes  
19. Vitamin B12:  No  Yes  
20. Vitamin C:  No  Yes  
21. Vitamin A:  No  Yes  
22. Vitamin D3:  No  Yes  
23. Vitamin K2:  No  Yes  
24. Vitamin E:  No  Yes  
25. Vitamin B12:  No  Yes  
26. Vitamin C:  No  Yes  
27. Vitamin A:  No  Yes  
28. Vitamin D3:  No  Yes  
29. Vitamin K2:  No  Yes  
30. Vitamin E:  No  Yes  
31. Vitamin B12:  No  Yes  
32. Vitamin C:  No  Yes  
33. Vitamin A:  No  Yes  
34. Vitamin D3:  No  Yes  
35. Vitamin K2:  No  Yes  
36. Vitamin E:  No  Yes  
37. Vitamin B12:  No  Yes  
38. Vitamin C:  No  Yes  
39. Vitamin A:  No  Yes  
40. Vitamin D3:  No  Yes  
41. Vitamin K2:  No  Yes  
42. Vitamin E:  No  Yes  
43. Vitamin B12:  No  Yes  
44. Vitamin C:  No  Yes  
45. Vitamin A:  No  Yes  
46. Vitamin D3:  No  Yes  
47. Vitamin K2:  No  Yes  
48. Vitamin E:  No  Yes  
49. Vitamin B12:  No  Yes  
50. Vitamin C:  No  Yes  
51. Vitamin A:  No  Yes  
52. Vitamin D3:  No  Yes  
53. Vitamin K2:  No  Yes  
54. Vitamin E:  No  Yes  
55. Vitamin B12:  No  Yes  
56. Vitamin C:  No  Yes  
57. Vitamin A:  No  Yes  
58. Vitamin D3:  No  Yes  
59. Vitamin K2:  No  Yes  
60. Vitamin E:  No  Yes  
61. Vitamin B12:  No  Yes  
62. Vitamin C:  No  Yes  
63. Vitamin A:  No  Yes  
64. Vitamin D3:  No  Yes  
65. Vitamin K2:  No  Yes  
66. Vitamin E:  No  Yes  
67. Vitamin B12:  No  Yes  
68. Vitamin C:  No  Yes  
69. Vitamin A:  No  Yes  
70. Vitamin D3:  No  Yes  
71. Vitamin K2:  No  Yes  
72. Vitamin E:  No  Yes  
73. Vitamin B12:  No  Yes  
74. Vitamin C:  No  Yes  
75. Vitamin A:  No  Yes  
76. Vitamin D3:  No  Yes  
77. Vitamin K2:  No  Yes  
78. Vitamin E:  No  Yes  
79. Vitamin B12:  No  Yes  
80. Vitamin C:  No  Yes  
81. Vitamin A:  No  Yes  
82. Vitamin D3:  No  Yes  
83. Vitamin K2:  No  Yes  
84. Vitamin E:  No  Yes  
85. Vitamin B12:  No  Yes  
86. Vitamin C:  No  Yes  
87. Vitamin A:  No  Yes  
88. Vitamin D3:  No  Yes  
89. Vitamin K2:  No  Yes  
90. Vitamin E:  No  Yes  
91. Vitamin B12:  No  Yes  
92. Vitamin C:  No  Yes  
93. Vitamin A:  No  Yes  
94. Vitamin D3:  No  Yes  
95. Vitamin K2:  No  Yes  
96. Vitamin E:  No  Yes  
97. Vitamin B12:  No  Yes  
98. Vitamin C:  No  Yes  
99. Vitamin A:  No  Yes  
100. Vitamin D3:  No  Yes  
101. Vitamin K2:  No  Yes  
102. Vitamin E:  No  Yes  
103. Vitamin B12:  No  Yes  
104. Vitamin C:  No  Yes  
105. Vitamin A:  No  Yes  
106. Vitamin D3:  No  Yes  
107. Vitamin K2:  No  Yes  
108. Vitamin E:  No  Yes  
109. Vitamin B12:  No  Yes  
110. Vitamin C:  No  Yes  
111. Vitamin A:  No  Yes  
112. Vitamin D3:  No  Yes  
113. Vitamin K2:  No  Yes  
114. Vitamin E:  No  Yes  
115. Vitamin B12:  No  Yes  
116. Vitamin C:  No  Yes  
117. Vitamin A:  No  Yes  
118. Vitamin D3:  No  Yes  
119. Vitamin K2:  No  Yes  
120. Vitamin E:  No  Yes  
121. Vitamin B12:  No  Yes  
122. Vitamin C:  No  Yes  
123. Vitamin A:  No  Yes  
124. Vitamin D3:  No  Yes  
125. Vitamin K2:  No  Yes  
126. Vitamin E:  No  Yes  
127. Vitamin B12:  No  Yes  
128. Vitamin C:  No  Yes  
129. Vitamin A:  No  Yes  
130. Vitamin D3:  No  Yes  
131. Vitamin K2:  No  Yes  
132. Vitamin E:  No  Yes  
133. Vitamin B12:  No  Yes  
134. Vitamin C:  No  Yes  
135. Vitamin A:  No  Yes  
136. Vitamin D3:  No  Yes  
137. Vitamin K2:  No  Yes  
138. Vitamin E:  No  Yes  
139. Vitamin B12:  No  Yes  
140. Vitamin C:  No  Yes  
141. Vitamin A:  No  Yes  
142. Vitamin D3:  No  Yes  
143. Vitamin K2:  No  Yes  
144. Vitamin E:  No  Yes  
145. Vitamin B12:  No  Yes  
146. Vitamin C:  No  Yes  
147. Vitamin A:  No  Yes  
148. Vitamin D3:  No  Yes  
149. Vitamin K2:  No  Yes  
150. Vitamin E:  No  Yes  
151. Vitamin B12:  No  Yes  
152. Vitamin C:  No  Yes  
153. Vitamin A:  No  Yes  
154. Vitamin D3:  No  Yes  
155. Vitamin K2:  No  Yes  
156. Vitamin E:  No  Yes  
157. Vitamin B12:  No  Yes  
158. Vitamin C:  No  Yes  
159. Vitamin A:  No  Yes  
160. Vitamin D3:  No  Yes  
161. Vitamin K2:  No  Yes  
162. Vitamin E:  No  Yes  
163. Vitamin B12:  No  Yes  
164. Vitamin C:  No  Yes  
165. Vitamin A:  No  Yes  
166. Vitamin D3:  No  Yes  
167. Vitamin K2:  No  Yes  
168. Vitamin E:  No  Yes  
169. Vitamin B12:  No  Yes  
170. Vitamin C:  No  Yes  
171. Vitamin A:  No  Yes  
172. Vitamin D3:  No  Yes  
173. Vitamin K2:  No  Yes  
174. Vitamin E:  No  Yes  
175. Vitamin B12:  No  Yes  
176. Vitamin C:  No  Yes  
177. Vitamin A:  No  Yes  
178. Vitamin D3:  No  Yes  
179. Vitamin K2:  No  Yes  
180. Vitamin E:  No  Yes  
181. Vitamin B12:  No  Yes  
182. Vitamin C:  No  Yes  
183. Vitamin A:  No  Yes  
184. Vitamin D3:  No  Yes  
185. Vitamin K2:  No  Yes  
186. Vitamin E:  No  Yes  
187. Vitamin B12:  No  Yes  
188. Vitamin C:  No  Yes  
189. Vitamin A:  No  Yes  
190. Vitamin D3:  No  Yes  
191. Vitamin K2:  No  Yes  
192. Vitamin E:  No  Yes  
193. Vitamin B12:  No  Yes  
194. Vitamin C:  No  Yes  
195. Vitamin A:  No  Yes  
196. Vitamin D3:  No  Yes  
197. Vitamin K2:  No  Yes  
198. Vitamin E:  No  Yes  
199. Vitamin B12:  No  Yes  
200. Vitamin C:  No  Yes  
201. Vitamin A:  No  Yes  
202. Vitamin D3:  No  Yes  
203. Vitamin K2:  No  Yes  
204. Vitamin E:  No  Yes  
205. Vitamin B12:  No  Yes  
206. Vitamin C:  No  Yes  
207. Vitamin A:  No  Yes  
208. Vitamin D3:  No  Yes  
209. Vitamin K2:  No  Yes  
210. Vitamin E:  No  Yes  
211. Vitamin B12:  No  Yes  
212. Vitamin C:  No  Yes  
213. Vitamin A:  No  Yes  
214. Vitamin D3:  No  Yes  
215. Vitamin K2:  No  Yes  
216. Vitamin E:  No  Yes  
217. Vitamin B12:  No  Yes  
218. Vitamin C:  No  Yes  
219. Vitamin A:  No  Yes  
220. Vitamin D3:  No  Yes  
221. Vitamin K2:  No  Yes  
222. Vitamin E:  No  Yes  
223. Vitamin B12:  No  Yes  
224. Vitamin C:  No  Yes  
225. Vitamin A:  No  Yes  
226. Vitamin D3:  No  Yes  
227. Vitamin K2:  No  Yes  
228. Vitamin E:  No  Yes  
229. Vitamin B12:  No  Yes  
230. Vitamin C:  No  Yes  
231. Vitamin A:  No  Yes  
232. Vitamin D3:  No  Yes  
233. Vitamin K2:  No  Yes  
234. Vitamin E:  No  Yes  
235. Vitamin B12:  No  Yes  
236. Vitamin C:  No  Yes  
237. Vitamin A:  No  Yes  
238. Vitamin D3:  No  Yes  
239. Vitamin K2:  No  Yes  
240. Vitamin E:  No  Yes  
241. Vitamin B12:  No  Yes  
242. Vitamin C:  No  Yes  
243. Vitamin A:  No  Yes  
244. Vitamin D3:  No  Yes  
245. Vitamin K2:  No  Yes  
246. Vitamin E:  No  Yes  
247. Vitamin B12:  No  Yes  
248. Vitamin C:  No  Yes  
249. Vitamin A:  No  Yes  
250. Vitamin D3:  No  Yes  
251. Vitamin K2:  No  Yes  
252. Vitamin E:  No  Yes  
253. Vitamin B12:  No  Yes  
254. Vitamin C:  No  Yes  
255. Vitamin A:  No  Yes  
256. Vitamin D3:  No  Yes  
257. Vitamin K2:  No  Yes  
258. Vitamin E:  No  Yes  
259. Vitamin B12:  No  Yes  
260. Vitamin C:  No  Yes  
261. Vitamin A:  No  Yes  
262. Vitamin D3:  No  Yes  
263. Vitamin K2:  No  Yes  
264. Vitamin E:  No  Yes  
265. Vitamin B12:  No  Yes  
266. Vitamin C:  No  Yes  
267. Vitamin A:  No  Yes  
268. Vitamin D3:  No  Yes  
269. Vitamin K2:  No  Yes  
270. Vitamin E:  No  Yes  
271. Vitamin B12:  No  Yes  
272. Vitamin C:  No  Yes  
273. Vitamin A:  No  Yes  
274. Vitamin D3:  No  Yes  
275. Vitamin K2:  No  Yes  
276. Vitamin E:  No  Yes  
277. Vitamin B12:  No  Yes  
278. Vitamin C:  No  Yes  
279. Vitamin A:  No  Yes  
280. Vitamin D3:  No  Yes  
281. Vitamin K2:  No  Yes  
282. Vitamin E:  No  Yes  
283. Vitamin B12:  No  Yes  
284. Vitamin C:  No  Yes  
285. Vitamin A:  No  Yes  
286. Vitamin D3:  No  Yes  
287. Vitamin K2:  No  Yes  
288. Vitamin E:  No  Yes  
289. Vitamin B12:  No  Yes  
290. Vitamin C:  No  Yes  
291. Vitamin A:  No  Yes  
292. Vitamin D3:  No  Yes  
293. Vitamin K2:  No  Yes  
294. Vitamin E:  No  Yes  
295. Vitamin B12:  No  Yes  
296. Vitamin C:  No  Yes  
297. Vitamin A:  No  Yes  
298. Vitamin D3:  No  Yes  
299. Vitamin K2:  No  Yes  
300. Vitamin E:  No  Yes  
301. Vitamin B12:  No  Yes  
302. Vitamin C:  No  Yes  
303. Vitamin A:  No  Yes  
304. Vitamin D3:  No  Yes  
305. Vitamin K2:  No  Yes  
306. Vitamin E:  No  Yes  
307. Vitamin B12:  No  Yes  
308. Vitamin C:  No  Yes  
309. Vitamin A:  No  Yes  
310. Vitamin D3:  No  Yes  
311. Vitamin K2:  No  Yes  
312. Vitamin E:  No  Yes  
313. Vitamin B12:  No  Yes  
314. Vitamin C:  No  Yes  
315. Vitamin A:  No  Yes  
316. Vitamin D3:  No  Yes  
317. Vitamin K2:  No  Yes  
318. Vitamin E:  No  Yes  
319. Vitamin B12:  No  Yes  
320. Vitamin C:  No  Yes  
321. Vitamin A:  No  Yes  
322. Vitamin D3:  No  Yes  
323. Vitamin K2:  No  Yes  
324. Vitamin E:  No  Yes  
325. Vitamin B12:  No  Yes  
326. Vitamin C:  No  Yes  
327. Vitamin A:  No  Yes  
328. Vitamin D3:  No  Yes  
329. Vitamin K2:  No  Yes  
330. Vitamin E:  No  Yes  
331. Vitamin B12:  No  Yes  
332. Vitamin C:  No  Yes  
333. Vitamin A:  No  Yes  
334. Vitamin D3:  No  Yes  
335. Vitamin K2:  No  Yes  
336. Vitamin E:  No  Yes  
337. Vitamin B12:  No  Yes  
338. Vitamin C:  No  Yes  
339. Vitamin A:  No  Yes  
340. Vitamin D3:  No  Yes  
341. Vitamin K2:  No  Yes  
342. Vitamin E:  No  Yes  
343. Vitamin B12:  No  Yes  
344. Vitamin C:  No  Yes  
345. Vitamin A:  No  Yes  
346. Vitamin D3:  No  Yes  
347. Vitamin K2:  No  Yes  
348. Vitamin E:  No  Yes  
349. Vitamin B12:  No  Yes  
350. Vitamin C:  No  Yes  
351. Vitamin A:  No  Yes  
352. Vitamin D3:  No  Yes  
353. Vitamin K2:  No  Yes  
354. Vitamin E:  No  Yes  
355. Vitamin B12:  No  Yes  
356. Vitamin C:  No  Yes  
357. Vitamin A:  No  Yes  
358. Vitamin D3:  No  Yes  
359. Vitamin K2:  No  Yes  
360. Vitamin E:  No  Yes  
361. Vitamin B12:  No  Yes  
362. Vitamin C:  No  Yes  
363. Vitamin A:  No  Yes  
364. Vitamin D3:  No  Yes  
365. Vitamin K2:  No  Yes  
366. Vitamin E:  No  Yes  
367. Vitamin B12:  No  Yes  
368. Vitamin C:  No  Yes  
369. Vitamin A:  No  Yes  
370. Vitamin D3:  No  Yes  
371. Vitamin K2:  No  Yes  
372. Vitamin E:  No  Yes  
373. Vitamin B12:  No  Yes  
374. Vitamin C:  No  Yes  
375. Vitamin A:  No  Yes  
376. Vitamin D3:  No  Yes  
377. Vitamin K2:  No  Yes  
378. Vitamin E:  No  Yes  
379. Vitamin B12:  No  Yes  
380. Vitamin C:  No  Yes  
381. Vitamin A:  No  Yes  
382. Vitamin D3:  No  Yes  
383. Vitamin K2:  No  Yes  
384. Vitamin E:  No  Yes  
385. Vitamin B12:  No  Yes  
386. Vitamin C:  No  Yes  
387. Vitamin A:  No  Yes  
388. Vitamin D3:  No  Yes  
389. Vitamin K2:  No  Yes  
390. Vitamin E:  No  Yes  
391. Vitamin B12:  No  Yes  
392. Vitamin C:  No  Yes  
393. Vitamin A:  No  Yes  
394. Vitamin D3:  No  Yes  
395. Vitamin K2:  No  Yes  
396. Vitamin E:  No  Yes  
397. Vitamin B12:  No  Yes  
398. Vitamin C:  No  Yes  
399. Vitamin A:  No  Yes  
400. Vitamin D3:  No  Yes  
401. Vitamin K2:  No  Yes  
402. Vitamin E:  No  Yes  
403. Vitamin B12:  No  Yes  
404. Vitamin C:  No  Yes  
405. Vitamin A:  No  Yes  
406. Vitamin D3:  No  Yes  
407. Vitamin K2:  No  Yes  
408. Vitamin E:  No  Yes  
409. Vitamin B12:  No  Yes  
410. Vitamin C:  No  Yes  
411. Vitamin A:  No  Yes  
412. Vitamin D3:  No  Yes  
413. Vitamin K2:  No  Yes  
414. Vitamin E:  No  Yes  
415. Vitamin B12:  No  Yes  
416. Vitamin C:  No  Yes  
417. Vitamin A:  No  Yes  
418. Vitamin D3:  No  Yes  
419. Vitamin K2:  No  Yes  
420. Vitamin E:  No  Yes  
421. Vitamin B12:  No  Yes  
422. Vitamin C:  No  Yes  
423. Vitamin A:  No  Yes  
424. Vitamin D3:  No  Yes  
425. Vitamin K2:  No  Yes  
426. Vitamin E:  No  Yes  
427. Vitamin B12:  No  Yes  
428. Vitamin C:  No  Yes  
429. Vitamin A:  No  Yes  
430. Vitamin D3:  No  Yes  
431. Vitamin K2:  No  Yes  
432. Vitamin E:  No  Yes  
433. Vitamin B12:  No  Yes  
434. Vitamin C:  No  Yes  
435. Vitamin A:  No  Yes  
436. Vitamin D3:  No  Yes  
437. Vitamin K2:  No  Yes  
438. Vitamin E:  No  Yes  
439. Vitamin B12:  No  Yes  
440. Vitamin C:  No  Yes  
441. Vitamin A:  No  Yes  
442. Vitamin D3:  No  Yes  
443. Vitamin K2:  No  Yes  
444. Vitamin E:  No  Yes  
445. Vitamin B12:  No  Yes  
446. Vitamin C:  No  Yes  
447. Vitamin A:  No  Yes  
448. Vitamin D3:  No  Yes  
449. Vitamin K2:  No  Yes  
450. Vitamin E:  No  Yes  
451. Vitamin B12:  No  Yes  
452. Vitamin C:  No  Yes  
453. Vitamin A:  No  Yes  
454. Vitamin D3:  No  Yes  
455. Vitamin K2:  No  Yes  
456. Vitamin E:  No  Yes  
457. Vitamin B12:  No  Yes  
458. Vitamin C:  No  Yes  
459. Vitamin A:  No  Yes  
460. Vitamin D3:  No  Yes  
461. Vitamin K2:  No  Yes  
462. Vitamin E:  No  Yes  
463. Vitamin B12:  No  Yes  
464. Vitamin C:  No  Yes  
465. Vitamin A:  No  Yes  
466. Vitamin D3:  No  Yes  
467. Vitamin K2:  No  Yes  
468. Vitamin E:  No  Yes  
469. Vitamin B12:  No  Yes  
470. Vitamin C:  No  Yes  
471. Vitamin A:  No  Yes  
472. Vitamin D3:  No  Yes  
473. Vitamin K2:  No  Yes  
474. Vitamin E:  No  Yes  
475. Vitamin B12:  No  Yes  
476. Vitamin C:  No  Yes  
477. Vitamin A:  No  Yes  
478. Vitamin D3:  No  Yes  
479. Vitamin K2:  No  Yes  
480. Vitamin E:  No  Yes  
481. Vitamin B12:  No  Yes  
482. Vitamin C:  No  Yes  
483. Vitamin A:  No  Yes  
484. Vitamin D3:  No  Yes  
485. Vitamin K2:  No  Yes  
486. Vitamin E:  No  Yes  
487. Vitamin B12:  No  Yes  
488. Vitamin C:  No  Yes  
489. Vitamin A:  No  Yes  
490. Vitamin D3:  No  Yes  
491. Vitamin K2:  No  Yes  
492. Vitamin E:  No  Yes  
493. Vitamin B12:  No  Yes  
494. Vitamin C:  No  Yes  
495. Vitamin A: <

#### Case #4

80 yr old Caucasian patient presents for a 1<sup>st</sup> visit. History of hypertension and hyperlipidemia

- > She states that she took a pill for osteoporosis for a few years and then was switched to denosumab. After 7 years on the drug, she developed a severe blistering skin rash. Saw 2 dermatologists and had 2 skin biopsies that were reported as non-specific inflammatory change.
- > She was advised to stop the denosumab and has not taken any osteoporosis therapy for the last 2 years.
- > She never smoked. No history of hip fracture in parent. No history of adult fracture. Not diabetic. Walks regularly for exercise
- > Reports adult height loss of 2 inches

Height: 4'8  
Weight: 100 pounds

37

#### Case #4

BMD:

T-scores: LS -3.6

Left femoral neck: -3.4

Total hip: -2.1

Change from previous: LS -14.6%

Total hip: -2.4%

FRAX: Major Osteoporotic Fracture: 27%

Hip: 12%

38

#### Case #4

How would you manage this patient?

Questions:

- > What pharmacologic therapy would you recommend?
- > What about patient counseling regarding choices?
- > Will you consider denosumab and would the patient take it?
- > What are the risks and benefits of options?
- > What did the patient prefer and why?

39

#### Case #5

67 yr old has her 1<sup>st</sup> bone density test. She reports menopause at age 48. On medication for hypertension and hyperlipidemia. No history of adult fracture, no hip fracture in parent, never smoked, occasional glass of wine. Exercises regularly

BMD:

Right and left total hip: -2.9 and -2.8

Femoral neck: -3.1 and -3.5

LS -1.2

FRAX:

Major Osteoporotic Fracture: 23.1%

Hip Fracture: 9.3%

40

#### Case #5

How would you manage this patient?

Questions:

- > Does she require a work-up regarding secondary causes of osteoporosis?
- > What pharmacologic therapy would you recommend?
- > What about patient counseling regarding choices?
- > What are the risks and benefits of options?
- > What did the patient prefer and why?
- > Is she a candidate for anabolic therapy?

41

#### Case #6

78 yr old black woman with dementia who lives with her husband. Has been taking oral bisphosphonate for 2 years. According to her husband, she takes it once a week and waits 30 minutes before eating, drinking, or laying down.

- > Normal kidney function. No history of adult fracture. No hip fracture in parent. No diabetes.

BMD:

Right and left total hip: -2.9 and -3.1

Right and left femoral neck: -2.8 and -3.1

LS: -1.2

FRAX: Major Osteoporotic Fracture: 11.6%

Hip: 4.7%

42

### Case #6

---

BMD Change from previous BMD 2 years ago:

- > LS -5.4%
  - > Left Total hip: -10.2%
  - > Right Total hip: -11.4%
- 

43

### Case #6

---

How would you manage this patient?

Questions:

- > What pharmacologic therapy would you recommend?
  - > What about patient counseling regarding choices?
  - > Will you consider denosumab and would the patient take it?
  - > What are the risks and benefits of options?
  - > What did the patient prefer and why?
- 

44

### Deep Dive

More cases from the trenches

---

45

### Just a Reminder: When considering plan...

---

- > Calcium and Vitamin D
  - > Labs
  - > Upcoming tooth extraction or tooth implant
  - > History of acid reflux
  - > Fall prevention
  - > Kidney function
  - > Mentation
  - > Insurance
  - > Patient's preference
- 

46

### Case #1

---

59 yo Black female with history of surgical menopause at age 34. Took estrogen for only a few years after surgery. Healthy. No kidney disease. No diabetes or hypertension.

BMD: right and left total hip: -2.4 -3.1  
right and left femoral neck: -2.6 -2.9  
Lumbar spine: -2.5

Is she osteoporotic?

Is she at high or very high risk of fracture?

What would you suggest for treatment?

What labs would you draw?

---

47

### Case #1

---

> Pt is interested in anabolic therapy after discussion of the option due to her low bone density.

> What are her options?

> What are the logistics in trying to start her on an anabolic agent?

---

48



## Case #2

74 yo black female: History per diagnostic center  
-hysterectomy at age 30. Relates steroid use of  
unspecified duration. History of RA.  
BMD: right and left hip: -0.7 and -0.5  
right and left femoral neck: -2.4 -1.9  
Loss at all levels from previous: 7% and 8.7%

49

## Information Provided by Testing Center

Country: US (Black) Name/ID: [ ] About the risk factors

**Questionnaire:**

1. Age (between 40 and 90 years) or Date of Birth: [ ]  
2. Sex:  Male  Female  
3. Weight (kg): [78.9]  
4. Height (cm): [167.6]  
5. Previous Fracture:  No  Yes  
6. Parent Fractured Hip:  No  Yes  
7. Current Smoking:  No  Yes  
8. Glucocorticoids:  No  Yes  
9. Rheumatoid arthritis:  No  Yes  
10. Secondary osteoporosis:  No  Yes  
11. Alcohol 3 or more units/day:  No  Yes  
12. Femoral neck BMD (g/cm<sup>2</sup>): [0.701] T-score: -2.4  
13. Femoral neck BMD (g/cm<sup>2</sup>): [ ]

BMD: 28.1  
10-year probability of fracture (%): 22  
Major osteoporosis: 7.3  
Hip Fracture: 7.3

50

## Recalculation After Taking History From Patient

Pt denies being on glucocorticoid therapy or having had a fracture.

Country: US (Black) Name/ID: [ ] About the risk factors

**Questionnaire:**

1. Age (between 40 and 90 years) or Date of Birth: [ ]  
2. Sex:  Male  Female  
3. Weight (kg): [78.9]  
4. Height (cm): [167.6]  
5. Previous Fracture:  No  Yes  
6. Parent Fractured Hip:  No  Yes  
7. Current Smoking:  No  Yes  
8. Glucocorticoids:  No  Yes  
9. Rheumatoid arthritis:  No  Yes  
10. Secondary osteoporosis:  No  Yes  
11. Alcohol 3 or more units/day:  No  Yes  
12. Femoral neck BMD (g/cm<sup>2</sup>): [0.701] T-score: -2.4  
13. Femoral neck BMD (g/cm<sup>2</sup>): [ ]

BMD: 28.1  
10-year probability of fracture (%): 9.2  
Major osteoporosis: 2.8  
Hip Fracture: 2.8

51

## Case #3

86 yo black female with hysterectomy at age 57.

BMD: right and left hip: -2.4 -2.3  
right and left femoral neck: -2.7 -2.1  
What questions would you ask the patient?  
Does she need labs?  
What would you prescribe?

52

## Case #4

71 yo white male: Pt has been on oral alendronate for 2 years.

BMD: right and left hip: -2.4 -2.5  
right and left femoral neck: -2.9 -2.6  
Lumbar spine: -0.6  
Values represent a loss of bone mineral density at the right and left hips: 2.7% and 2.4%

53

## Case #4

- > What is his fracture risk?
- > What is the patient's desire for treatment?
- > What is the patient's insurance coverage?
- > What are the important medical history questions?
- > What labs would you draw?
- > How would you treat this patient?
- > Would you refer this patient?

54

#### Case #4

---

- > Serum calcium, PTH, testosterone free and total, TSH, protein electrophoresis: WNL
  - > 24 hour urine:
    - Calcium, creatinine, sodium: WNL
    - N-Telopeptide: elevated to 784 (Normal range male: 21 - 83)
  - > What does this mean? Pt has been on an anti-resorptive agent for 2 years
- 

55

#### Case #5

---

- 72 yo white male with current smoking history and diabetes.
- BMD: right and left total hip: -2.1 -3.4  
right and left femoral neck: -1.5 -2.2
- FRAX: MOF: 13.8 Hip: 6.4
- What labs would you order?  
What are your options for pharmacologic therapy?
- 

56

#### Case #6

---

- 79 yo female with menopause at age 53. Pt has never taken any medication for fracture prevention.
- BMD: right and left total hip: -3.5 -3.4  
right and left femoral neck: -3.5 -3.1
- FRAX: MOF: 34% Hip: 16.6
- What are your options for treating this patient?  
What labs would you obtain?
- 

57

#### Case #6

---

- > What is her fracture risk?
  - > What is the patient's desire for treatment?
  - > What is the patient's insurance coverage?
  - > What are the important medical history questions?
  - > What labs would you draw?
  - > How would you treat this patient?
  - > Would you refer this patient?
- 

58

#### Case # 6

---

- > What would you discuss regarding sequencing with anabolic therapy?
  - > What are the risks and benefits?
  - > If pt agrees and she did, what are the logistics?
- 

59

#### Case #7

---

- 74 yo black female with surgical menopause at age 49
- BMD: Total hip: -2.4 -2.5  
Femoral neck: -2.4 -2.3  
LS: -0.6
- FRAX: MOF: 7.1% Hip: 2.1%
- 

60

### Case #7

---

- > What is her fracture risk?
  - > What is the patient's desire for treatment?
  - > What is the patient's insurance coverage?
  - > What are the important medical history questions?
  - > What labs would you draw?
  - > How would you treat this patient?
  - > Would you refer this patient?
- 

61

### Case #8

---

78 yo white female with history of surgical menopause at age 37.

BMD: Right and left total hip: -0.2 -0.4  
Right and left femoral neck: -1.7 -1.3  
LS: 1.4  
FRAX: MOF: 20% Hip: 4.6%

---

62

### Case #8

---

- > What is her fracture risk?
  - > What is the patient's desire for treatment?
  - > What is the patient's insurance coverage?
  - > What are the important medical history questions?
  - > What labs would you draw?
  - > How would you treat this patient?
  - > Would you refer this patient?
- 

63

### Resources

---

**Bone Health and Osteoporosis Foundation**  
[www.bonehealthandosteoporosis.org](http://www.bonehealthandosteoporosis.org)

**North American Menopause Society (NAMS)**  
[www.menopause.org](http://www.menopause.org)

---

64

### TREASURE YOUR BONES AT EVERY AGE!

---



65

### Bibliography

---

- > Adler RA, EL-Hajj, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 2016;31(1):19-35
  - > Camacho PM, Petak SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines For The Diagnosis and Treatment of Post Menopausal Osteoporosis- 2020 Update. *endocrine Practice.* 2020;26:5-6.
  - > Felicia Cosman, M.D., Daria B. Crittenden, M.D., Jonathan D. Adachi, M.D., et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. *N Engl J Med* 2016; 375:1532-1543
  - > Cossman F. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture. *Endocrine Practice.* Accepted for Publication. 2020
  - > Curry SJ, Krist AH, Owens DK, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. *Jama.* 2018;319(24):2521-2531.
- 

66

## Bibliography

---

- > Diab D, Watts N, Use of Drug Holidays in Women Taking Bisphosphonates. NAMS Practice Bulletin, Released April 1, 2013.
  - > Edwards BJ. Osteoporosis Risk Calculators. *J Clin Densitom.* 2017;20(3):379-386.
  - > LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int.* 2022. Epub 2022/04/29. doi: 10.1007/s00198-021-05900-y. PubMed PMID: 35478046.
  - > Miller P, Hattersley G, Ris B J "Effect of Abaloparatide vs Placebo in New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial" *JAMA* 2016;316(7): 722-733. doi:10.1001/jama.2016.11136
- 

67

## Bibliography

---

- > Nelson, H. D., Haney, E. M., Chou, R., Dana, T., Fu, R., & Bougatsos, C. (2010). Screening for osteoporosis: Systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 77. *AHRQ Publication No. 10-05145-EF-1*. Rockville, MD: Agency for Healthcare Research and Quality.
  - > NAMS Position Statement. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. *Menopause: The Journal of The North American Menopause Society*, Vol. 28, No. 9, pp. 973-997. DOI: 10.1097/GME.0000000000001831. © 2021 by The North American Menopause Society
  - > Siris, E., & Delmas, P. D. (2008). Assessment of 10-year absolute fracture risk: A new paradigm with worldwide application. *Osteoporosis International*, (19)4, 383-384. doi: 10.1007/s00198-008-0564-8
  - > Tymlos [package insert]. St. Waltham, MA: Radius Health; 2017.
  - > World Health Organization Collaborating Center for Metabolic Bone Diseases. (n.d.). "FRAX" tool, online. Retrieved from [www.shef.ac.uk/frax](http://www.shef.ac.uk/frax)
- 

68